





Electronic Data Integrity

By Praxis Life Sciences
a division of Treximo


Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from Praxis is prohibited.

© 2020 Praxis Life Sciences. All rights reserved.




Electronic Data Integrity

© Copyright 2020 by Praxis Life Sciences. All rights reserved. No part of these materials may be reproduced or transmitted in any form without the written permission of Praxis




v.20.05

1



Your Praxis Facilitator

- Debra Bartel, MBA, CQA, PMP
- VP, Life Sciences QA
- 30 years experience specializing in software quality assurance, validation and regulatory compliance, Information Systems project management, and process design.
- Prior to joining Praxis, held management positions in the pharmaceutical industry in both Quality Assurance and Information Systems organizations
- Active member of American Society for Quality (ASQ), Northeastern Illinois Section, Software Division




© 2020 Praxis Life Sciences
a division of Treximo

2

2

Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from Praxis is prohibited.

© 2020 Praxis Life Sciences. All rights reserved.







PRAXIS
life sciences

Intro to Praxis Life Sciences


VALIDATION CENTER

- Consulting
- Audit Services
- Training
- Library

Follow us!   

 Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 3


3



PRAXIS
life sciences

Target Audience


- Industries**
 - Pharmaceutical & Biologics
 - Medical Device
 - Clinical Studies
 - Blood Products
- Regions**
 - Operating in the US
 - Selling to the US Market
- Personnel**
 - IT Personnel and Managers
 - Quality Personnel and Managers
 - Auditors and Audit Managers

 Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 4


4


Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from Praxis is prohibited.

© 2020 Praxis Life Sciences. All rights reserved.


 **Webinar Outline**


- 1 • Data Integrity Regulatory History**
- 2 • Data Integrity Terminology**
- 3 • Electronic Data Integrity Principles**
- 4 • Examples of Data Integrity Risks**



 Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 5

5

 **Data Integrity
Regulatory History**
Part 1



6

6

PRAXIS
life sciences

“Data Integrity” Is Not New!







21 CFR 211.100 “... shall be documented at the time of performance ”	21 CFR 820.180 “... records shall be legible and shall be stored to minimize deterioration and to prevent loss. ”	21 CFR 56.115 “... records shall be accessible for inspection and copying...”
21 CFR 600.12 “...records shall be legible and indelible , shall identify the person immediately responsible , shall include dates... ”	21 CFR 211.194 “... showing that the original records have been reviewed for accuracy, completeness. ”	21 CFR 820.180 “... records stored in automated data processing systems shall be backed up. ”
21 CFR 820.180 “All records required by this part shall be retained for a period of time equivalent to...”	21 CFR 211.180 “... may be retained either as original records or as true copies. ”	21 CFR 606.160 “Records shall be maintained concurrently with the performance of each significant step...”

vc Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 7

7

PRAXIS
life sciences

“Data Integrity” in the Paper World


		
		

vc Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 8

8

PRAXIS life sciences

“Data Integrity” for Electronic World



Validation Center™


© 2020 Praxis Life Sciences
a division of Treximo

9

9

PRAXIS life sciences

Regulations Brought Some Clarity

<p>Part 11</p> <p>Persons who use closed systems to create, modify, maintain, or transmit electronic records shall employ procedures and controls designed to ensure the authenticity, integrity, and, when appropriate, the confidentiality of electronic records</p>		<p>Part 11</p> <p>Persons who use electronic signatures based upon use of identification codes in combination with passwords shall employ controls to ensure their security and integrity.</p>
<p>Annex 11</p> <p>Risk management should be applied throughout the lifecycle of the computerised system taking into account patient safety, data integrity and product quality.</p> <p>As part of a risk management system, decisions on the extent of validation and data integrity controls should be based on a justified and documented risk assessment of the computerised system.</p>		

Validation Center™

© 2020 Praxis Life Sciences
a division of Treximo

10

10

PRAXIS
life sciences

But GxP Violations Persisted...

In recent years, FDA has increasingly observed CGMP violations involving data integrity during CGMP inspections.

This is troubling because ensuring data integrity is an important component of industry's responsibility to ensure the safety, efficacy, and quality of drugs, and of FDA's ability to protect public health.

These data integrity-related CGMP violations have led to numerous regulatory actions, including Warning Letters, Import Alerts, and Consent Decrees ¹

¹ quotes from Data Integrity and Compliance with Drug CGMP, FDA, December 2018

Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 11

11

PRAXIS
life sciences

Guidance History

2015 – March: MHRA GMP Data Integrity Definitions and Guidance for Industry
2016 – April: FDA [DRAFT] Data Integrity and Compliance with CGMP Guidance for Industry
2016 – June: WHO Guidance on Good Data and Records Management Practices
2016 – August: EMA Questions and Answers: Good Manufacturing Practice – Data Integrity Compliance
2016 – July and August: PIC/S [DRAFT] Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments
2018 – March: MHRA 'GxP' Data Integrity Guidance and Definitions
2018 – November: PIC/S [DRAFT] Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments
2018 – December: FDA Data Integrity and Compliance with Drug CGMP


Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 12

12

Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from Praxis is prohibited.

© 2020 Praxis Life Sciences. All rights reserved.

PRAXIS life sciences **Clarity At Last!**



vc Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 13

13

PRAXIS life sciences **www.VALIDATIONCENTER.COM**

A PRAXIS LIFE SCIENCES knowledge center & resource +1 (847) 295-7160 View Cart My Account Logout


VALIDATION CENTER ABOUT US CONSULTING AUDITS TRAINING LIBRARY CONTACT

Praxis Life Sciences has everything you need for Computer System Validation and Software Quality Assurance

- Consulting
- Audit Services
- Training
- Library


vc Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 14

14




Data Integrity Terminology

Part 2



15



Integrity

Integrity (noun) | Dictionary.com

1. Adhering to moral and ethical principles; honesty
2. Whole, entire, undiminished

FDA	MHRA	PIC/S
Complete	Complete	Complete
Consistent	Consistent	Consistent
Accurate	Accurate	Accurate
	Trustworthy	
	Reliable	

Validation Center™ | © 2020 Praxis Life Sciences a division of Treximo | 16

16

PRAXIS
life sciences

Data | Metadata

Data **66**

Metadata

Information about the data that makes the data meaningful

- 2017-02-27 15:23:01 GMT when data generated
- Joe L. Smith lab analyst who ran test
- GX-0032-A lab instrument that generated the data
- mg unit of measure
- 2017-02-27 13:23:01 GMT 66 original test result
- 2017-02-27 13:32:32 GMT 67 changed by J.Jones
- 2017-02-28 11:00:06 GMT deleted by M.Cooper
- Audit trail


vc Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 17

17


PRAXIS
life sciences

Static Data | Dynamic Data

Static Data: Data that is fixed



Dynamic Data: Data that allows user interaction which could alter the result



vc Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 18

18

PRAXIS
life sciences

Original Data | True Copy

Original Data: Data in its original format

True Copy: Copy of Original Data that has been

- 1) Verified
 - Signed, dated by the verifier, *OR*
 - Generated through a validated process
- 2) Contains the same information as the Original Data – *including the metadata*

The diagrams illustrate four scenarios for creating a True Copy from Original Data:

- Original Data (Paper) → True Copy (Paper)
- Original Data (Server) → True Copy (Paper)
- Original Data (Paper) → True Copy (Server)
- Original Data (Server) → True Copy (Server)

Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 19

19

PRAXIS
life sciences


Audit Trail

Electronic Record that allows for reconstruction of events related to the creation, modification or deletion of an electronic record

- Computer Generated
- Independently Recorded
- Date and time stamped
- Author identified
- Secure
- Does not obscure previously recorded information
- Retained for as long as the subject record
- Suitable for reviewing and copying

Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 20

20




PRAXIS
life sciences

ALCOA

- A** • **ATTRIBUTABLE**
• Clear identification of who performed the task
- L** • **LEGIBLE**
• Human readable
- C** • **CONTEMPORANEOUSLY RECORDED**
• Recorded in real time
- O** • **ORIGINAL or TRUE COPY**
• Initial capture or complete copy, including metadata
- A** • **ACCURATE**
• Correct

Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 21

21




PRAXIS
life sciences

ALCOA +

- A** • **ATTRIBUTABLE**
• Clear identification of who performed the task
- L** • **LEGIBLE**
• Human readable
- C** • **CONTEMPORANEOUSLY RECORDED**
• Recorded in real time
- O** • **ORIGINAL or TRUE COPY**
• Initial capture or complete copy
- A** • **ACCURATE**
• Correct
- C** • **COMPLETE**
• Whole (nothing missing)
- C** • **CONSISTENT**
• Self-consistent
- E** • **ENDURING**
• Lasting for the retention period
- A** • **AVAILABLE**
• Readily retrievable


Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 22

22




Electronic Data Integrity Principles


Part 3



23





Access Restrictions



Expectation Actions attributable to person who performed the task

- Require User ID + Password for access to add/change/delete
- Prohibit sharing of User IDs
- Prohibit re-use of User IDs
- Prohibit sharing of Passwords... including sharing with IT Support staff
- Eliminate use of Generic accounts, e.g., System Admin, Vendor Maintenance
- Require periodic revision of Passwords
- Log-out or require re-authentication after period of inactivity
- Lock-out after defined number of invalid Password attempts



 Validation Center™

© 2020 Praxis Life Sciences
a division of Treximo

24

24

PRAXIS
life sciences

Access Restrictions

Expectation Access limited to only features needed to perform job

- Limit access to minimum possible, especially access to:
 - Change, delete, inactivate/void data and records
 - Set up new users and change access levels
 - Change system settings and configuration, e.g., date/time, access levels, product specifications, processing parameters, test methods
 - Change software
- Segregate duties to reduce the likelihood of data integrity issues, for example:
 - Limit access to change critical settings, delete records, etc. to persons outside of the organization responsible for the electronic data and records

Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 25

25



PRAXIS
life sciences

Access Restrictions

Scenario 1	Scenario 2	Scenario 3
<p>A Doc Center user has access to author, edit and publish SOPs.</p> <p>Should this user have access to the change validated document workflows?</p> <p>Should this user be able to give access to another user?</p>	<p>A Lab user has access to enter product testing results.</p> <p>Should this user have access to change the product specifications?</p> <p>Delete results for failing tests?</p>	<p>IT technical support user has access to apply software patches.</p> <p>Should this user have access to author, edit, and delete production data?</p> <p>Should this user be able to give access to another user?</p>


Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 26


26

 **Access Restrictions** 



Expectation Controls for authorizing and tracking user access

- Implement formal procedure for managing system access... including IT, vendors
 - Define training requirements for each access level
 - Define responsibility for authorizing requests for each access level
 - Document and approve all access requests
 - Retain access authorization records and training records
 - Implement process for temporary access, e.g., for system maintenance
 - Immediately remove access when leaving company, changing positions, or ending temporary access
 - Periodically audit access levels and associated users



 Validation Center™ © 2020 Praxis Life Sciences
a division of Treximo 27


27

 **Access Restrictions** 

FDA WARNING LETTER

All employees had administrator privileges and shared one user name, so actions **could not be attributed** or traced to specific individuals.
This exposed your electronic data to manipulation and/or deletion without traceability.

Analysts also **shared the username and password for the Windows operating system** for the GC workstations and no computer lock mechanism had been configured to prevent unauthorized access to the operating systems.

 Validation Center™ © 2020 Praxis Life Sciences
a division of Treximo 28

28

PRAXIS
life sciences

Access Restrictions

FDA WARNING LETTER

Our investigators observed that information technology **(IT) staff** at your facility **share usernames and passwords** to access your electronic storage system for data.

Your IT staff can delete or change directories and files without identifying individuals making changes.

After a previous inspection in which FDA observed similar deficiencies, you committed to eliminate these and other data integrity vulnerabilities

Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 29

29

PRAXIS
life sciences

Access Restrictions

FDA WARNING LETTER

During the inspection, our investigator reviewed data from your high performance liquid chromatography (HPLC) analysis for release testing, including assay and impurity testing.

Your quality control analysts used administrator privileges to change the controls for the time and date settings and manipulate file names to overwrite injections and delete original HPLC test data.

Analysts also routinely **turned HPLC audit trails on and off.**

Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 30

30

PRAXIS
life sciences

Access Restrictions

FDA WARNING LETTER

Your firm's computer system for storing certificates of analysis (CoA), which document whether a drug meets specifications, does not have sufficient controls to prevent unauthorized changes to a CoA after quality unit approval.

During the inspection, a manager demonstrated for our investigator how **results on an already finalized CoA could be manipulated after the formal quality unit approval.**

Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 31

31

PRAXIS
life sciences

Audit Trail Reviews

Expectation Systems with audit trails that meet Part 11 requirements

Automatically computer generated

Secured from change or deletion



Including date, time, user
Also includes reason for change/deletion where required by predicate rule

Provides visibility to all previously recorded information, i.e. Allows for reconstruction of the events that led to the current state, including creation, alteration, deletion

Available for review


Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 32


32

 **Audit Trail Reviews** 



Expectation Audit trails allow detection of potential data integrity issues

- Verify that situations such as these can be detected by looking at the audit trail:
 - Alteration of data or records – *especially after approval*
 - Data and record deletion
 - Aborted lab testing runs
 - Testing into compliance
 - Changes to critical process parameters
 - Back-dating
- If needed, work with technical expert or software vendor to improve audit trail ‘readability’, e.g., via new views, reports



 Validation Center™ © 2020 Praxis Life Sciences
a division of Treximo 33


33

 **Audit Trail Reviews** 

Expectation Review of audit trails during approval of **critical** data

- For **critical data and records**, include an audit trail review in the approval processes (SOPs)
 - Examples** of critical data and records:
 - Product testing results and sample run sequences
 - Manufacturing process parameters
 - Study conclusions
 - **Responsibility:** Same role that has responsibility for data review, per regulations, e.g., Quality Unit for manufacturing Batch Record Review
 - **Method:** Review audit trail online or via validated report



 Validation Center™ © 2020 Praxis Life Sciences
a division of Treximo 34

34

PRAXIS
life sciences

Audit Trail Reviews

Expectation Risk-based review of audit trails for **other GxP data**

- For **non-critical GxP data and records**, implement processes (SOPs) for risk-based review of audit trails
 - **Frequency:** Based on criticality, e.g., to patients, products, study outcomes and likelihood of data integrity issues, e.g., unauthorized deletions or changes
 - **Responsibility:**
 - Organization responsible for record content
 - Checked by QA during internal audits
 - **Method:** Review audit trail online or via validated report
 - **Document** outcome of each review

Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 35

35

PRAXIS
life sciences

Audit Trails


FDA WARNING LETTER

Your firm uses software to document, maintain, and track customer complaints electronically.

However, as stated by your firm's Director of Quality Assurance (QA) & Regulatory Affairs (RA) during the inspection, the **software does not generate time-stamped audit trails** to independently record the date and time of operator entries and actions that create, edit, or modify electronic records.

Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 36

36



PRAXIS life sciences **Audit Trail Reviews** 2

FDA WARNING LETTERS

A file containing the moisture content results for an API batch had been deleted.


This **deletion was not identified and reviewed as part of your batch release decision.**

Your firm lacks systems to ensure that all electronic data generated in your Quality Control laboratory is secure and remains unaltered.

Your firm's **review of laboratory data does not include a review of an audit trail** or revision history to determine if unapproved changes have been made.

VC Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 37

37



PRAXIS life sciences **Electronic Copies** 3

Expectation "True Copy" principles applied for all GxP copies

- Implement policies that must be applied whenever electronic records are copied or migrated for GxP purposes
 - All content and meaning from the original must be preserved
 - All of the information must be accurate and complete
 - All of the metadata (e.g., the audit trail) must be retained
 - The record must remain readily available
- Implement procedures (SOPs) for creating and verifying "True Copies"
- Validate programs used to create "True Copies"

VC Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 38

38

PRAXIS life sciences **Electronic Copies** **3**

FDA WARNING LETTERS

Due to a transition to a new complaint handling computer system, the following **complaints were missing a code and were not included in trending:**

- a) 99 complaints for inflammatory mass
- b) 88 complaints for Dysarthria. When this data was added to the system, three separate signals exceeded threshold
- c) 11 complaints for Loculation
- d) 104 complaints for Incision Pain


VC Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 39

39

PRAXIS life sciences **Back Up, Protection & Retention** **4**



Expectation Records protected from loss

- Implement back-up and disaster recovery processes for
 - Records, data, metadata
 - Software, system settings, configurations, and run-time parameters
- Establish risk-based frequency for
 - Performing back ups
 - Auditing back up media
 - Executing disaster recovery tests
- Establish risk-based standards for location of back up media
- Validate back up and recovery processes.




VC Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 40

40



 **Back Up, Protection & Retention** 

Expectation Records protected from loss

- Retain electronic records in a location with physical security:
 - Secured room with minimal number of persons able to access
 - Appropriate temperature and humidity controls
 - Protection from fire and water damage
- Implement controls to secure from external (cyber) hazards, such as:
 - Record corruption or damage
 - Record theft


 Validation Center™ © 2020 Praxis Life Sciences
a division of Treximo 41


41

 **Back Up, Protection & Retention** 

Expectation Records readily available for the entire retention period

- Document the retention period for all GxP records generated and/or retained electronically
 - Include metadata (e.g., audit trail) in the scope for retention
- If records are archived outside the system:
 - Validate the archival process
 - Retest when technology is changed
 - Document the procedure for accessing or restoring the records and metadata
 - Periodically test the access or restore process



 Validation Center™ © 2020 Praxis Life Sciences
a division of Treximo 42

42

PRAXIS
life sciences

Back-Ups

4

FDA WARNING LETTERS

Your Quality Unit, after consulting with the Information Technology (IT) department, stated they were unable to retrieve the original electronic raw data because **back-up discs were unreadable**.

Your quality unit then stated that back-up disks have been unreadable since at least 2013.

You **did not include** metadata with **audit trails** in your back-up.

vc Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 43

43

PRAXIS
life sciences

Back-Ups

4

FDA WARNING LETTER

You stated that your study coordinator used a sponsor-provided laptop to enter data into the eCRF for each subject.



You stated that during the closeout visit, the **sponsor's monitor took the laptop** computer with the eCRFs.

You further explained that the actual eCRF data disks were never obtained from the sponsor.

It was your responsibility to retain eCRFs copies for 2 years after the investigation was discontinued and FDA was notified.

vc Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 44

44


 **Back-Ups** 

FDA WARNING LETTER



You confirmed that there are no meeting minutes for the year during which two meetings were held.

You explain that due to a computer crash **all minutes and data for that time frame were lost.** You stated that you would “re-create” the meeting minutes and provide them at a later date.

It is inappropriate and an unacceptable record keeping practice for the IRB to re-create minutes.


 Validation Center™ © 2020 Praxis Life Sciences
a division of Treximo 45

45


 **Validation** 

Expectation Electronic systems validated for company-specific uses

- Confirm that purchased (COTS) and cloud (SaaS) systems have been validated for company-specific uses, e.g.:
 - Workflows
 - Settings / Configurations, e.g., drop down lists of critical values, security groups, audit trail settings, password expiration
 - Calculations and formulas
 - User-created reports
 - Connections to company equipment
- Perform validation for any gaps found in vendor’s generic “validation”

 Validation Center™ © 2020 Praxis Life Sciences
a division of Treximo 46

46



PRAXIS life sciences

Validation

5

FDA WARNING LETTER

Off-the-shelf software (Microsoft SharePoint) is being used to manage quality system documents for document control and approval.


Firm has **failed to adequately validate this software to ensure that it meets your needs and intended uses.**

There were 2 versions of the CAPA & Customer Complaint procedure.

Your firm has failed to validate the SharePoint software to meet your needs for maintaining document control and versioning.

vc Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 47

47



PRAXIS life sciences

Validation

5

FDA WARNING LETTER

Your firm uses software in in-process and final product testing.

The validation compared the measurement with the optical comparator and the air gage.

However, your firm also uses the software for conducting a surface test. The software is used for measuring the top profile during manufacturing.

The software **validation did not address this capability.**

vc Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 48

48

PRAXIS
life sciences

Unacceptable Practices

6

Expectation Practices where data can 'disappear without a trace' eliminated

EXAMPLES

Eliminate practices such as:

- Recording data on a piece of paper, and then **discarding the paper** after the data is transcribed into the system
- Storing electronic data in **temporary memory**, in a manner that allows for manipulation, before creating a permanent record
- Placing records (e.g., chromatograms) in long-term storage at the **end of the day** rather than upon completion of the run.

Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 49

49

PRAXIS
life sciences

Unacceptable Practices

6

Expectation Practices that enable "testing into compliance" eliminated

"Testing into Compliance"
Re-sampling, re-testing, or re-processing with the goal of achieving a specific result or overcoming an unacceptable result

- Update laboratory procedures (SOPs):
 - Define acceptable reasons (if any) for re-sampling, re-testing, and reprocessing
 - Define how to document and authorize use of the acceptable reasons for re-sampling, re-testing, and re-processing, e.g., *brief explanation in audit trail, full explanation and supervisor approval in lab notebook*
 - Require retention of **ALL** test results

Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 50

50

Unacceptable Practices

FDA WARNING LETTER

Our investigator found that your GC system lacked controls to prevent manipulation, data deletion, and unauthorized access.

For example, operators responsible for generating CGMP records had full administrator rights to access the computers containing temporary data prior to routine transfer of the data to a server.

Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 51

51

Unacceptable Practices

FDA WARNING LETTER



Without providing scientific justification, you **repeated analyses until you obtained acceptable results.**

You failed to investigate original out-of-specification or otherwise undesirable test results, and you only documented passing test results in logbooks and preparation notebooks.

You relied on these manipulated test results and incomplete records to support batch release decisions.


Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 52


52

 **Reports of Data Integrity Issues** 



Expectation Potential data integrity issues investigated & corrected

- Implement formal procedures (SOPs) to manage reported and suspected data integrity lapses through the quality systems, e.g., within the CAPA program.
 - Determine of the extent of the issue, e.g. limited to one area or product vs. systemic
 - Determine the effect of the issue on patient safety, product quality, or data reliability
 - Determine the root cause
 - Ensure that corrective action is taken
 - Monitor effectivity and new instances is same issue



 Validation Center™ © 2020 Praxis Life Sciences
a division of Treximo 53

53


 **Reports of Data Integrity Issues** 

FDA WARNING LETTER



A “File Note” signed by the QC Head established that the printed **data** used for batch disposition decisions from the hard drive was **not necessarily** the **complete** data for a batch.

Our inspection found that this data was selected for use.

The audit trail capability of this QC “commercial” laboratory instrument was not enabled, even after creation of the “File Note.”

 Validation Center™ © 2020 Praxis Life Sciences
a division of Treximo 54

54


 **Reports of Data Integrity Issues** 

FDA WARNING LETTER



Your Quality Control unit failed to detect that IR spectra were being substituted by a laboratory employee, misrepresenting the actual results of the tested incoming material.

You responded that you "fired the chemist responsible for falsifying the data." You also indicate that you found another incident of data manipulation involving the IR Spectra.

Your response is incomplete because you have not provided a more **comprehensive plan to ensure the integrity of all data** used to **assess the quality and purity of APIs** manufactured at your facility.

 Validation Center™ © 2020 Praxis Life Sciences
a division of Treximo 55

55


 **Reports of Data Integrity Issues** 

FDA WARNING LETTER


Your firm failed to prepare batch production and control records with complete information relating to the production and control of each batch.

Specifically, your electronic data logs did not retain alarm messages indicating when certain manufacturing parameters exceed their limits during production operations.

In response to this letter, provide a **retrospective review** to determine whether potential breaches of your manufacturing parameters had any **effect on the quality of products released to the market.**

 Validation Center™ © 2020 Praxis Life Sciences
a division of Treximo 56


56


 **Outsourced Activities** 

Expectation Data Integrity practices for GxP service & material providers



Examples of GxP providers:
Third Party manufacturing, testing, warehousing, distribution, clinical trial execution

- Supplier Qualification
 - Verify providers' data integrity practices during initial qualification
 - Periodically check providers' data integrity practices during re-qualification
- Quality Agreements
 - Include responsibilities and expectations regarding data integrity




 Validation Center™ © 2020 Praxis Life Sciences
a division of Treximo 57


57

 **Outsourced Systems** 


Expectation Data Integrity practices for cloud (SaaS, PaaS, IaaS) systems

- Supplier Qualification
 - Verify providers' data integrity features and practices during initial qualification
 - Periodically check providers' data integrity practices during re-qualification
- Contracts, Quality Agreements and/or Services Level Agreements (SLAs)
 - Include responsibilities and expectations to ensure data integrity




 Validation Center™ © 2020 Praxis Life Sciences
a division of Treximo 58


58

 **Training** 10


Expectation All personnel trained in detecting data integrity issues

- Periodical training in
 - Responsibilities for data integrity
 - Detection of potential data integrity issues
 - Reporting of potential data integrity issues
- Include all employees and temporary staff with responsibilities for:
 - Creation and modification of GxP data and records
 - Retention and protection of GxP data and records
 - Development and maintenance of the electronic systems used to generate, retain, and store GxP data and records




 Validation Center™ © 2020 Praxis Life Sciences
a division of Treximo 59

59




Examples of Data Integrity Risks

Part 4




60

60



61



62

PRAXIS
life sciences

Scenario 3

Scenario: Lab Instrument Software and Electronic Lab Notebook (ELN)

QC Laboratory

Electronic Lab Notebook





Computer Room

vc Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 63

63

PRAXIS
life sciences

How Can Praxis Help?


-  **Data Integrity Audits & Compliance Plans**
-  **Computer System Validation Services**
-  **Online and Classroom CSV Training**
-  **ValidationCenter.com Library of Template and SOPs**


vc Validation Center™ © 2020 Praxis Life Sciences a division of Treximo 64

64

Reproduction or re-transmission in any form or by any means, electronic or mechanical without prior written permission from Praxis is prohibited.

© 2020 Praxis Life Sciences. All rights reserved.



 **Thank You!**

Thanks for your interest in Electronic Data Integrity




Any questions about what we have discussed today?
Please, feel free to contact me:


Deb Bartel

+1 (847) 295-7160

dbartel@praxislifesciences.com

validationcenter.com | praxislifesciences.com

Follow us!   

 Validation Center™ © 2020 Praxis Life Sciences
a division of Treximo 65

65